Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Long-Term Capital Lease Obligation : ¥1 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Hangzhou Bio-Sincerity Pharma-Tech Co Long-Term Capital Lease Obligation?

Hangzhou Bio-Sincerity Pharma-Tech Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1 Mil.

Hangzhou Bio-Sincerity Pharma-Tech Co's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥1 Mil) but then declined from Dec. 2023 (¥1 Mil) to Mar. 2024 (¥1 Mil).

Hangzhou Bio-Sincerity Pharma-Tech Co's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (¥8 Mil) to Dec. 2022 (¥0 Mil) but then increased from Dec. 2022 (¥0 Mil) to Dec. 2023 (¥1 Mil).

Hangzhou Bio-Sincerity Pharma-Tech Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Hangzhou Bio-Sincerity Pharma-Tech Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Bio-Sincerity Pharma-Tech Co Long-Term Capital Lease Obligation Chart

Hangzhou Bio-Sincerity Pharma-Tech Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

19.58

8.14

0.93

Hangzhou Bio-Sincerity Pharma-Tech Co Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.19	-	-	0.93	0.91

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Hangzhou Bio-Sincerity Pharma-Tech Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Hangzhou Bio-Sincerity Pharma-Tech Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Bio-Sincerity Pharma-Tech Co Ltd (SZSE:301096) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Dongguan Road, 2nd Floor, Building 8, Jinsheng Technology Park, Binjiang District, Hangzhou, CHN

Website

https://www.hzbio-s.com

Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a pharmaceutical technology research and development company. The company's business covers drug discovery, pharmaceutical research, clinical research, and registration application.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Headlines

No Headlines